SimBioSys, the creators of the first digital precision medicine platform, TumorSight, and Ricoh 3D, a leader in manufacturing custom medical devices, have partnered to explore the potential of AI combined with advanced 3D printing and how both technologies could be leveraged for improving surgical procedures and personalized patient care in breast cancer treatment.
The results of this collaboration were presented at the American Society of Breast Surgeons conference, where Ricoh 3D for Healthcare and SimBioSys showcased some of their first AI-generated, 3D-printed breast cancer models. The event became a space to discuss various applications of integrated technologies among the breast surgeon community.
Gary Turner, managing director at Ricoh USA, said, “Through a collaboration with SimBioSys, we hope to not just envision a new future for medical treatment but help actively create it.”
While the workflow created by SimBioSys and Ricoh 3D for Healthcare is intended for educational purposes, and not diagnostic use just yet, this is a first step in developing such technologies for clinical use.
In turn, Jyoti Palaniappan, Commercial Director of SimBioSys, highlighted the importance of the companies’ presence at ASBrS. According to Palaniappan, the synergistic partnership could provide surgeons and patients with a clearer understanding of complex cancer surgeries, even prior to the initial incision. With this collaboration, who knows? The future of breast cancer treatment could be looking far more hopeful before surgery even begins.
